Faron Pharmaceuticals Oy (FARON.HE)
| Previous Close | 2.8950 |
| Open | 3.2100 |
| Bid | 3.1550 x N/A |
| Ask | 3.2000 x N/A |
| Day's Range | 3.0000 - 3.4500 |
| 52 Week Range | 1.3520 - 4.5900 |
| Volume | |
| Avg. Volume | 99,397 |
| Market Cap | 224.75M |
| Beta (5Y Monthly) | -0.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4800 |
| Earnings Date | Mar 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireFaron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024
Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, Faron’s co-founders, have been nominated as one of three finalists in the ‘SMEs’ category of prestigious European Patent Office AwardsNominated in recognition of research developing bexmarilimab, an investigational immunotherapy optimising clinical outcomes in cancer treatmentVoting now open for “Popular Prize” award ahead of ceremony on July 9 via dedicated link: Sirpa Jalkanen and Markku Jalkanen | Epo.org TURKU, Finland and BOSTON, May 16, 2024 (GLO
- GlobeNewswire
Faron Confirms Plans for the Coming Months Under New Leadership
Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next monthIncoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for obtaining marketing approval for MDS patients that have failed HMA TURKU, Finland and BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activa
- GlobeNewswire
Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML
Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients.4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up.While data do not yet allow the precise estimation of median overall survival, the survival benefit seen with the current follow-up already for these 5 first patients is very encouraging. This compares favorably to what has been seen with contempor
